AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...

The government website is meant to connect Americans with drug companies to buy prescriptions directly with their own money.

AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.

The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...

Q4 2025 earnings call highlights: record sales, Skyrizi/Rinvoq momentum, 2026 guidance ($67B) and risks—read key takeaways.

Cigna Corporation (NYSE:CI) Q4 2025 Earnings Call Transcript February 5, 2026 Cigna Corporation beats earnings expectations.

CVS Health®   today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...

The choice between the two might come down to each investor's goals and risk tolerance.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.

Since taking over as CEO of the Cambridge biotech more than three years ago, Chris Viehbacher has cut hundreds of jobs and reduced expenses, in part by removing drugs from its research pipeline.

By diving deeper into the dynamics of high-cost claims, employers can uncover valuable insights that pave the way for smart, ...

CVS Caremark will begin offering osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity and ...